WO2018135843A2 - Souche de lactobacillus fermentum pouvant empêcher la perte de cheveux, favoriser la pousse des cheveux, ou améliorer la fonction sexuelle, et composition comprenant cette souche - Google Patents
Souche de lactobacillus fermentum pouvant empêcher la perte de cheveux, favoriser la pousse des cheveux, ou améliorer la fonction sexuelle, et composition comprenant cette souche Download PDFInfo
- Publication number
- WO2018135843A2 WO2018135843A2 PCT/KR2018/000757 KR2018000757W WO2018135843A2 WO 2018135843 A2 WO2018135843 A2 WO 2018135843A2 KR 2018000757 W KR2018000757 W KR 2018000757W WO 2018135843 A2 WO2018135843 A2 WO 2018135843A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- strain
- lactobacillus
- kccm11910p
- ceb
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 230000036299 sexual function Effects 0.000 title claims abstract description 17
- 230000003779 hair growth Effects 0.000 title claims abstract description 16
- 241000186840 Lactobacillus fermentum Species 0.000 title claims description 26
- 229940012969 lactobacillus fermentum Drugs 0.000 title claims description 26
- 201000004384 Alopecia Diseases 0.000 title abstract description 55
- 230000003676 hair loss Effects 0.000 title abstract description 50
- 208000024963 hair loss Diseases 0.000 title abstract description 50
- 241000186660 Lactobacillus Species 0.000 claims description 63
- 229940039696 lactobacillus Drugs 0.000 claims description 63
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 38
- 230000003658 preventing hair loss Effects 0.000 claims description 19
- 235000012000 cholesterol Nutrition 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 239000012141 concentrate Substances 0.000 claims description 13
- 230000001737 promoting effect Effects 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 241000555281 Brevibacillus Species 0.000 claims description 10
- 230000004130 lipolysis Effects 0.000 claims description 4
- 241000192132 Leuconostoc Species 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 241000194036 Lactococcus Species 0.000 claims description 2
- 241000186429 Propionibacterium Species 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 210000004209 hair Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 235000008504 concentrate Nutrition 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 240000006024 Lactobacillus plantarum Species 0.000 description 7
- 201000001880 Sexual dysfunction Diseases 0.000 description 7
- 231100000872 sexual dysfunction Toxicity 0.000 description 7
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 231100000360 alopecia Toxicity 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000534616 Brevibacillus reuszeri Species 0.000 description 3
- 241000194031 Enterococcus faecium Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- -1 for example Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 241000218671 Ephedra Species 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000186612 Lactobacillus sakei Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 244000000231 Sesamum indicum Species 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000013527 bean curd Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052573 porcelain Inorganic materials 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000010865 sewage Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 206010015120 Erection increased Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005118 dietary health Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000005053 stress perception Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Definitions
- the present invention relates to a novel strain having a hair loss prevention, promoting hair growth or improving sexual function and a composition comprising the same.
- the cause of hair loss is not well known yet, but there are reports of possible causes such as genetic factors, hormonal abnormalities, and immunological abnormalities.
- the present invention is to provide a novel lactic acid bacteria strain effective for preventing hair loss, promoting hair growth or improving sexual function.
- the present invention is to provide a composition for preventing hair loss, promoting hair growth or improving sexual function that can be safely used without side effects.
- the novel Lactobacillus fermentum ( Lactobacillus fermentum ) Provides a KCCM11910P strain.
- the morphological characteristics of the strain are Gram-positive bacteria, have a nucleotide sequence of SEQ ID NO: 1, and have 99% homology with Lactobacillus percentage as analyzed by 16s rRNA partial sequencing. Accordingly, the present inventors deposited the newly isolated Lactobacillus pertumtum KCCM11910P at the Korean Culture Center of Microorganisms (120-861, Hongje-2ga-gil, Seodaemun-gu, Seoul, Korea) on October 7, 2016. The strain is isolated from the traditional Korean food Cheonggukjang. The strain is effective in preventing hair loss, promoting hair growth, improving sexual function, lowering cholesterol, and / or lipolysis.
- Another aspect of the invention relates to a culture of Lactobacillus permanent KCCM11910P, concentrates thereof, or dried products thereof.
- the novel isolated strain of the present invention can be cultured through a conventional method for culturing Bacillus or Lactobacillus genus.
- the medium may be natural or synthetic medium.
- the carbon source of the medium for example, glucose, sucrose, dextrin, glycerol, starch and the like can be used, and as the nitrogen source, peptone, meat extract, yeast extract, dried yeast, soybean, ammonium salt, nitrate and other organic or inorganic Nitrogen containing compounds may be used, but are not limited to these components.
- Inorganic salts contained in the medium include magnesium. Manganese, calcium. Iron, potassium and the like can be used, but are not limited thereto.
- culture temperature conditions of the newly isolated strain of the present application can be incubated for 12 hours to 4 days in the temperature range of 20 ⁇ 40 °C.
- medicinal preparations such as seoritae, baekshou, sukjihwang, licorice, cheongung, tofu, cinnamon, donkey, Seokpo, red sesame, ephedra, ginger, white porcelain, cheoncho, horseback riding, mandrel, etc.
- the culture of the newly isolated strain may be a culture stock solution including the cells, and may also be a culture cell from which the culture supernatant is removed or concentrated.
- the culture composition may further include components necessary for culturing Bacillus or Lactobacillus strains, as well as components that act synergistically to the growth of Bacillus or Lactobacillus strains, the composition according to the conventional techniques in the art It can be easily selected by those who have it.
- the state of the strain may be a liquid state or dry state
- the drying method is possible, but not limited to ventilation drying, natural drying, spray drying and freeze drying.
- the present invention relates to a composition
- a composition comprising the Lactobacillus permanent strain of the present invention, a culture thereof, a concentrate thereof, or a dried product thereof.
- the Lactobacillus fermentum strain may specifically be Lactobacillus fermentum KCCM11910P, but is not limited thereto.
- the composition may be a food composition or a pharmaceutical composition for preventing hair loss, promoting hair growth, or improving sexual function, and further, has a lipolytic effect and / or a cholesterol lowering effect.
- One aspect of the food composition may be a food, health food, dietary supplement, or health functional food composition.
- One aspect of the pharmaceutical composition may be a quasi-drug or a pharmaceutical preparation.
- the composition is Seoryae, Baekshou, Sukjihwang, licorice, Cheongung, tofu, cinnamon, Angelica, Seokchangpo, Red sesame, ephedra, prickly pear, pine needles, pine flower, celticus, jimo, ginger, white porcelain, cheoncho, horseback riding, bay
- Herbal ingredients effective for preventing hair loss or promoting hair growth such as herbal preparations such as a typewriter, extracts thereof, or mixtures thereof; Or may further comprise a pharmaceutical component such as minoxidil or finasteride.
- the composition is Brevibacillus Genus , Lactobacillus Genus, Lactococcus Genus, Propionibacterium Genus, Enterocuccus Genus, Strains such as the Bifidobacterium genus may be further included.
- Brevibacillus reuszeri E.g. KCCM11911P
- Enterococcus faecium e.g. KCCM11909P
- Leuconostoc mesenteroides e.g. KCCM11827P
- leukonostock holzafel e.g. KCCM11830P
- Lactobacillus sakei e.g. KCCM11841P
- Culture or mixtures thereof.
- composition may further comprise collagen.
- the composition of the present invention comprises Lactobacillus fermentum (eg KCCM11910P) strains of 5 x 10 4 CFU / ml to 5 x 10 10 CFU / ml, preferably 5 x 10 4 CFU / ml to 5 x 10 8 LFU Bacillus percentages of CFU / ml (eg KCCM11910P).
- the composition may be administered 30ml to 100ml per dose, once to four times a day at the above concentration.
- composition of the present invention may further include a pharmaceutically or food acceptable carrier, and may be formulated with the carrier to be provided as a food or medicine.
- the term "pharmaceutically or food acceptable carrier” refers to a carrier or diluent that does not stimulate the organism and does not inhibit the biological activity and properties of the administered strain.
- composition may be formulated in a variety of oral or parenteral formulations, but may preferably be formulated in a liquid oral solution.
- acceptable pharmaceutical or food acceptable carriers are sterile and physiologically compatible carriers, including saline, sterile water, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol and these
- saline sterile and physiologically compatible carriers
- sterile water sterile water
- buffered saline albumin injectable solutions
- dextrose solution dextrose solution
- maltodextrin solution glycerol
- glycerol glycerol
- diluents, dispersants, surfactants, binders and lubricants may be additionally added to formulate into liquid formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
- the dosage is from 5 x 10 4 to 5 x 10 8 CFU / ml of Lactobacillus permanent (eg KCCM11910P) strain, preferably from 1 x 10 6 to 1 x 10 8 CFU / ml.
- the amount of Lactobacillus permanent eg KCCM11910P may be administered from 30ml to 100ml per dose once to four times a day.
- 50 ml per dose may be administered 2 to 4 times per day in an amount of 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml of Lactobacillus percentage (eg KCCM11910P). More specifically, the amount of 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml of Lactobacillus percentage (eg, KCCM11910P) may be administered once to twice daily with 50ml to 100ml per dose. More specifically, 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml of Lactobacillus percentage (eg KCCM11910P) is administered once 50ml to 100ml 30 minutes before breakfast, and 50ml to 30 minutes before dinner or before bedtime. 100 ml can be administered once.
- 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml of Lactobacillus percentage eg KCCM11910P
- 100 ml can be administered once.
- Formulations for oral administration comprising the Lactobacillus fermentum of the present invention (e.g., KCCM11910P) include, for example, tablets, troches, lozenges, water-soluble or oily suspensions, prepared powders or granules, emulsions, hard or soft capsules, Syrups or elixirs.
- binders such as cellulose or gelatin
- excipients such as dicalcium phosphate, disintegrants such as corn starch or sweet potato starch, stearic acid Lubricants such as magnesium, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax may be included, and the capsule formulation may further contain a liquid carrier such as fatty oil in addition to the aforementioned substances.
- the daily dosage of the composition or Lactobacillus permanent will vary depending on the patient's weight, age, sex, health condition, treatment, prevention or major symptoms, time of administration, method of administration and severity. But may be about 0.0001 mg / kg to about 10 g / kg, specifically about 0.01 mg / kg to about 500 mg / kg, and may be administered or applied once to six times a day, for example, once to four times a day. Can be.
- the lactobacillus permanents (eg, KCCM11910P) in the composition may be in liquid or dry state, preferably in liquid form. Drying methods may be, but not limited to, ventilation drying, natural drying, spray drying and freeze drying.
- the Lactobacillus permanentum of the present invention e.g., KCCM11910P
- One aspect of the present invention relates to a composition for preventing hair loss or promoting hair growth, comprising a Lactobacillus latement (eg, KCCM11910P) strain or a culture thereof, a concentrate thereof, or a dried product thereof.
- a Lactobacillus latement eg, KCCM11910P
- KCCM11910P Lactobacillus latement
- Another aspect of the invention comprises administering to a subject a therapeutic or prophylactically effective amount of a Lactobacillus pertumtum (eg KCC11910P) strain or culture thereof, concentrate or dried product thereof to prevent hair loss or promote hair growth. It relates to a method for preventing hair loss or a method for treating hair loss.
- the therapeutic or prophylactically effective amount may vary depending on the weight, age, sex, health condition, treatment, prevention, or major symptoms, time of administration, administration method, and severity of the patient, as described above.
- Lactobacillus permanum (eg KCCM11910P) strains of 5 ⁇ 10 4 to 5 ⁇ 10 8 CFU / ml, preferably 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml of Lactobacillus percentagement (eg KCCM11910P 30 ml to 100 ml per dose may be administered once to four times daily. In one example, 50 ml per dose may be administered 2 to 4 times per day in an amount of 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml of Lactobacillus percentage (eg KCCM11910P).
- the amount of 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml of Lactobacillus percentage may be administered once to twice daily with 50ml to 100ml per dose. More specifically, 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml of Lactobacillus percentage (eg KCCM11910P) is administered once 50ml to 100ml 30 minutes before breakfast, and 50ml to 30 minutes before dinner or before bedtime. 100 ml can be administered once.
- One aspect of the present invention relates to a composition for improving sexual dysfunction, including Lactobacillus fermentum (eg, KCCM11910P) strain or a culture thereof, a concentrate thereof, or a dried product thereof.
- the sexual dysfunction improvement may be, for example, an improvement in erectile dysfunction.
- another aspect of the present invention comprises administering to a subject for the prevention or treatment of sexual dysfunction a therapeutic or prophylactically effective amount of a Lactobacillus latement (eg, KCCM11910P) strain or its culture, its concentrate or its dry matter.
- the present invention relates to a method for preventing or treating sexual dysfunction.
- the therapeutic or prophylactically effective amount is the same as described above.
- One aspect of the present invention relates to a composition for lowering cholesterol, comprising a Lactobacillus fermentum (eg, KCCM11910P) strain or a culture thereof, a concentrate thereof, or a dried product thereof.
- a Lactobacillus fermentum eg, KCCM11910P
- high cholesterol comprising administering to a subject a therapeutically or prophylactically effective amount of a Lactobacillus pertumtum (eg, KCCM00000) strain or culture thereof, concentrate or dried product thereof to lower cholesterol
- a method for preventing or treating bloodemia is the same as described above.
- One aspect of the present invention relates to a composition for lipolysis comprising a Lactobacillus pertumtum (eg, KCCM11910P) strain or a culture thereof, a concentrate thereof, or a dried product thereof.
- a composition for lipolysis comprising a Lactobacillus pertumtum (eg, KCCM11910P) strain or a culture thereof, a concentrate thereof, or a dried product thereof.
- another aspect of the invention comprises administering to a subject for the prevention or treatment of hyperlipidemia a therapeutic or prophylactically effective amount of a Lactobacillus fermentum (eg, KCCM11910P) strain or culture thereof, concentrate or dried product thereof , A method of preventing or treating hyperlipidemia.
- the therapeutic or prophylactically effective amount is the same as described above.
- Lactobacillus fermentum strain of the present invention eg, KCCM11910P
- a composition comprising the same is effective for preventing hair loss, promoting hair growth or improving sexual function.
- Lactobacillus permanent eg KCCM11910P
- a composition comprising the same can be used safely to prevent hair loss, promote hair growth, lower cholesterol or improve sexual function without side effects.
- 1 is a hair comparison photograph before and after (about 2 months) taking Lactobacillus fermentum Ceb-ch-002 (KCCM11910P) strain.
- KCCM11910P Lactobacillus permanent Ceb-ch-002
- FIG. 4 is a comparison of hair before and after taking Lactobacillus permanent Ceb-ch-002 (KCCM11910P) and Brevibacillus lugeri Ceb-ch-003 (KCCM11911P).
- FIG. 5 is a hair comparison photograph before and after taking Lactobacillus permanent Ceb-ch-002 (KCCM11910P) and Brevibacillus rugeri Ceb-ch-003 (KCCM11911P).
- FIG. 6 is a comparison of hair before and after taking Lactobacillus permanent Ceb-ch-002 (KCCM11910P) and Brevibacillus rugeri Ceb-ch-003 (KCCM11911P).
- Figure 7 shows Lactobacillus permanent Ceb-ch-002 (KCCM11910P) and kimchi extract bacteria Leukonstock Holzpellelli Ceb-kc-003 ( Leuconostoc Hair comparison picture before and after taking holzapfelii Ceb-kc-003 (KCCM11830P).
- Figure 8 is a graph showing the cholesterol lowering effect compared to Lactobacillus plantarum strain Lactobacillus fermentum Ceb-ch-002 (KCCM11910P) strain and other lactic acid strains.
- Figure 9 is a graph showing the NO production concentration compared to Lactobacillus plantarum strain Lactobacillus fermentum Ceb-ch-002 (KCCM11910P) strain and other lactic acid strains.
- Cheonggukjang a traditional Korean food, was collected, and the obtained sample was diluted in stages and incubated in BHI solid medium (Difco, USA) added with 3% sodium chloride for 24 hours at 37 ° C. The predominant strain was isolated from the sample. Selected colonies were purely separated by culturing in a new medium over 3 times, and the pure cultured cells were stored in a medium to which 20% glycerol was added and stored at below 70 ° C.
- morphological and biochemical investigations were performed primarily.
- the morphological features were Gram-stained and Gram-positive.
- the analysis was performed by 16s rRNA partial sequencing to analyze the taxonomic characteristics. As a result, it was confirmed that the isolate had a nucleotide sequence of SEQ ID NO: 1, and the isolated strain had 99% homology with Lactobacillus percentage.
- the inventors deposited the newly isolated Lactobacillus permanent Ceb-ch-002 at the Korean Culture Center of Microorganisms (120-861, Hongje-2ga-gil, Seodaemun-gu, Seoul) on October 7, 2016. Was deposited.
- strain powder The strain was lyophilized to prepare strain powder.
- Lactobacillus permanent Ceb-ch-002 (KCCM11910P) strain cultures obtained in Example 1 were subjected to 1 ⁇ 10 6 to 1 month to 2 months in a total of three males aged 48, 54 and 55 with alopecia. An amount of 1 ⁇ 10 8 CFU / ml of Lactobacillus permanent Ceb-ch-002 (KCCM11910P) was orally administered daily between 50 ml and 100 ml twice daily in the morning and evening.
- the number of hairs falling out after hair washing once at 10-day intervals before and after administration of the strain was 10 days, 20 days and 30 days.
- Hair loss number before and after taking Test subject Taking date 48 year old male 54 year old male 55 year old male Before taking 55 hair loss 44 hair loss 38 hair loss 10 days after taking 36 hair loss 33 hair loss 26 hair loss 20 days after taking 21 hair loss 19 hair loss 20 hair loss 30 days after taking 12 hair loss 5 hair loss 8 hair loss
- Lactobacillus fermentum Ceb-ch-002 (KCCM11910P) strain of the present invention is effective in preventing hair loss, and is also effective in treating hair loss by remarkably improving hair thickness, quantity and shine.
- Example 3 Lactobacillus Permanent Ceb -ch-002 ( KCCM11910P ) Strains Brevibacillus rugeri Ceb -ch-003 ( KCCM11911P ) Hair loss prevention effect of strain combination
- the culture solution of Lactobacillus permanent Ceb-ch-002 (KCCM11910P) strain obtained in Example 1 was isolated from Cheonggukjang, and the Korean Culture Center of Microorganisms, Hongje-2ga, Seodaemun-gu, Seoul, October 7, 2016. Brevibacillus deposited with the accession number KCCM11911P at -120-861) reuszeri ) Cultures of Ceb-ch-003 (KCCM11911P) strains were administered to a total of three men 55 years, 53 years and 48 years old with alopecia for 1 to 2 months.
- Specific dosing methods include 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml of Lactobacillus permanent Ceb-ch-002 (KCCM11910P) at 25 ml to 50 ml, 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml Brevibacillus reuszeri Ceb-ch-003 (KCCM11911P) 25 ml to 50 ml per dose were administered orally twice daily.
- Hair loss number before and after taking Test subject Taking date 55 year old male 53 year old male 48 year old male Before taking 60 hair loss 55 hair loss 57 hair loss 10 days after taking 45 hair loss 43 hair loss 45 hair loss 20 days after taking 23 hair loss 27 hair loss 36 hair loss 30 days after taking 10 hair loss 7 hair loss 13 hair loss
- Lactobacillus fermentum Ceb-ch-002 (KCCM11910P) strain of the present invention is another strain, Brevibacillus rugeri ( Brevibacillus) reuszeri )
- Ceb-ch-003 (KCCM11911P) strain When used in combination with Ceb-ch-003 (KCCM11911P) strain, it can be seen that it is more effective in preventing hair loss.
- Example 4 Lactobacillus Permanent Ceb -ch-002 ( KCCM11910P ) Hair Loss Prevention Effects of Strains and Leukonostock Holzafelly Ceb-kc-003 (KCCM11830P) Strains
- the culture medium of Lactobacillus permantum Ceb-ch-002 (KCCM11910P) strain obtained in Example 1 and the culture medium of leukonostock Holzafelly Ceb-kc-003 (KCCM11830P) strain isolated from kimchi were 66 years old with hair loss symptoms. A male was administered for 4 months.
- Specific dosing methods include 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml of Lactobacillus permanent Ceb-ch-002 (KCCM11910P) at 25 ml to 50 ml, 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml Rukono Stock Holz Felice Ceb-kc-003 (KCCM11830P) 25 ml to 50 ml per dose were administered orally twice daily.
- Hair loss before and after taking Test subject Taking date 66 year old male Before taking 45 hair loss 10 days after taking 41 hair loss 20 days after taking 20 hair loss 30 days after taking 15 hair loss
- Example 5 Lactobacillus Permanent Ceb -ch-002 ( KCCM11910P ) Strains Enterococcus Paesium KCCM11909P Hair loss prevention effect of strain combination
- Lactobacillus permanent Ceb-ch-002 (KCCM11910P) strain obtained in Example 1 and cultures of the Enterococcus faecium KCCM11909P strain were administered to a 60-year-old male with alopecia for 3 months.
- Specific administration methods include 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml of Lactobacillus permanent Ceb-ch-002 (KCCM11910P) 25 ml to 50 ml per time, 1 ⁇ 10 6 to 1 ⁇ 10 8 CFU / ml of enterocock
- Hair loss number before and after taking Test subject Taking date 60 year old male Before taking 45 hair loss 10 days after taking 42 hair loss 20 days after taking 27 hair loss 30 days after taking 23 hair loss
- Lactobacillus Permanent Ceb-ch-002 (KCCM11910P) strain powder
- 1 mg / ml to 5 mg / ml Lactobacillus Permanent Ceb-ch-002 (KCCM11910P) lyophilized powder solution
- 1 mg / ml to 5 mg / ml Lactobacillus plantarum powder solution was used as a control, respectively.
- the cholesterol removal ability defined in the present invention can be specifically measured according to the following method:
- Lactobacillus permanent Ceb-ch-002 Lactobacillus plantarum 1mg / ml 21% 11% 2mg / ml 27% 16% 3mg / ml 39% 22% 4mg / ml 51% 31% 5mg / ml 62% 35%
- Lactobacillus fermentum Ceb-ch-002 (KCCM11910P) strain powder of the present invention is effective in lowering cholesterol in proportion to the concentration, which is significantly higher than other lactobacillus Lactobacillus plantarum . .
- Example 7 Lactobacillus Permanent Ceb -ch-002 ( KCCM11910P ) Improvement of sexual function of strain And prevention effect
- a total of 5 males aged 50 to 70 who are smokers or non-smokers with or without sexual dysfunction are 1 x 10 6 to 1 x 10 8 CFU / ml of Lactobacillus latex Ceb-ch-002 (KCCM11910P). ) was orally administered once daily to twice daily in an amount of 50 ml to 100 ml per time. Before and after the administration of the strain was allowed to self-evaluate the number of dawn erection, erection, erection persistence at monthly intervals.
- Lactobacillus latent Ceb-ch-002 (KCCM11910P) strain powder of the present invention can be confirmed that there is a prophylactic effect of sexual dysfunction, and further, the therapeutic effect on sexual dysfunction.
- Lactobacillus permanent Ceb-ch-002 Lactobacillus plantarum 1 ⁇ g / ml 3.7 ( ⁇ M) 2.5 ( ⁇ M) 10 ⁇ g / ml 4.0 ( ⁇ M) 2.9 ( ⁇ M) 20 ⁇ g / ml 4.6 ( ⁇ M) 3.1 ( ⁇ M) 30 ⁇ g / ml 5.2 ( ⁇ M) 3.3 ( ⁇ M) 40 ⁇ g / ml 6.4 ( ⁇ M) 3.5 ( ⁇ M) 50 ⁇ g / ml 7.1 ( ⁇ M) 3.5 ( ⁇ M)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne une nouvelle souche ayant pouvant empêcher la perte de cheveux, favoriser la pousse des cheveux, ou améliorer la fonction sexuelle; et une composition comprenant cette souche.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0009281 | 2017-01-19 | ||
KR1020170009281A KR101791088B1 (ko) | 2017-01-19 | 2017-01-19 | 탈모 예방, 발모 촉진 또는 성기능 개선능이 있는 락토바실러스 퍼멘텀 균주 및 이를 포함하는 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2018135843A2 true WO2018135843A2 (fr) | 2018-07-26 |
WO2018135843A3 WO2018135843A3 (fr) | 2019-02-07 |
Family
ID=60301486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/000757 WO2018135843A2 (fr) | 2017-01-19 | 2018-01-16 | Souche de lactobacillus fermentum pouvant empêcher la perte de cheveux, favoriser la pousse des cheveux, ou améliorer la fonction sexuelle, et composition comprenant cette souche |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101791088B1 (fr) |
WO (1) | WO2018135843A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020096059A1 (fr) * | 2018-11-09 | 2020-05-14 | ニチニチ製薬株式会社 | Agent externe pour la pousse des cheveux ou la prévention de la perte des cheveux |
CN113797137A (zh) * | 2021-10-29 | 2021-12-17 | 浙江宜格企业管理集团有限公司 | 一种具有滋养强韧眉毛功能的何首乌提取物及制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101791088B1 (ko) * | 2017-01-19 | 2017-10-31 | (주)코엔바이오 | 탈모 예방, 발모 촉진 또는 성기능 개선능이 있는 락토바실러스 퍼멘텀 균주 및 이를 포함하는 조성물 |
KR102640916B1 (ko) * | 2021-12-17 | 2024-02-28 | 주식회사 더가든오브내추럴솔루션 | 리기락토바실러스 루미니스 속 lmt16-11의 균주, 그 배양액, 또는 이의 추출물을 유효성분으로 포함하는 화장료 조성물 |
KR102578662B1 (ko) * | 2023-05-23 | 2023-09-19 | 주식회사 락토메이슨 | 열처리 유산균 리모시락토바실러스 퍼멘텀 lm1020을 포함하는 탈모 완화 및 발모 촉진용 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100815255B1 (ko) | 2007-06-08 | 2008-03-19 | 이득식 | 락토바실러스 퍼멘텀 js 균주를 함유하는 장류 및 그제조방법 |
KR100929880B1 (ko) | 2009-08-12 | 2009-12-04 | 심태흥 | 측백나무 잎을 포함하는 발모 촉진 또는 탈모 방지용 조성물 및 이의 제조방법 |
KR100942794B1 (ko) * | 2009-11-03 | 2010-02-18 | 한남대학교 산학협력단 | 성기능 개선 효과를 나타내는 아르기닌 유도체 및 이의 염, 이를 포함하는 성기능 개선용 조성물 그리고 이의 제조방법 |
WO2012141540A2 (fr) * | 2011-04-13 | 2012-10-18 | 씨제이제일제당 (주) | Nouvelle souche isolée de lactobacillus fermentum ayant une activité inhibitrice d'infection virale |
KR101511976B1 (ko) * | 2013-11-01 | 2015-04-14 | 주식회사한국야쿠르트 | 면역증강 활성을 가지는 신규한 락토바실러스 퍼멘텀 hy7301 및 이를 유효성분으로 함유하는 제품 |
KR20150056208A (ko) * | 2013-11-15 | 2015-05-26 | 한국생명공학연구원 | 신규 락토바실러스 퍼멘텀 sj8256 균주 및 이의 용도 |
KR101791088B1 (ko) * | 2017-01-19 | 2017-10-31 | (주)코엔바이오 | 탈모 예방, 발모 촉진 또는 성기능 개선능이 있는 락토바실러스 퍼멘텀 균주 및 이를 포함하는 조성물 |
-
2017
- 2017-01-19 KR KR1020170009281A patent/KR101791088B1/ko active IP Right Grant
-
2018
- 2018-01-16 WO PCT/KR2018/000757 patent/WO2018135843A2/fr active Application Filing
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020096059A1 (fr) * | 2018-11-09 | 2020-05-14 | ニチニチ製薬株式会社 | Agent externe pour la pousse des cheveux ou la prévention de la perte des cheveux |
CN113164531A (zh) * | 2018-11-09 | 2021-07-23 | 日本尼奇制药株式会社 | 用于生发或防止脱发的外用剂 |
JPWO2020096059A1 (ja) * | 2018-11-09 | 2021-09-30 | ニチニチ製薬株式会社 | 育毛用又は脱毛防止用外用剤 |
US20210393708A1 (en) * | 2018-11-09 | 2021-12-23 | Nichinichi Pharmaceutical Co., Ltd. | External agent for hair growth or hair loss prevention |
CN113164531B (zh) * | 2018-11-09 | 2023-12-15 | 日本尼奇制药株式会社 | 用于生发或防止脱发的外用剂 |
JP7426100B2 (ja) | 2018-11-09 | 2024-02-01 | ニチニチ製薬株式会社 | 育毛用又は脱毛防止用外用剤 |
US12128074B2 (en) * | 2018-11-09 | 2024-10-29 | Nichinichi Pharmaceutical Co., Ltd. | External agent for hair growth or hair loss prevention |
CN113797137A (zh) * | 2021-10-29 | 2021-12-17 | 浙江宜格企业管理集团有限公司 | 一种具有滋养强韧眉毛功能的何首乌提取物及制备方法 |
CN113797137B (zh) * | 2021-10-29 | 2024-04-16 | 浙江宜格企业管理集团有限公司 | 一种具有滋养强韧眉毛功能的何首乌提取物及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
KR101791088B1 (ko) | 2017-10-31 |
WO2018135843A3 (fr) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018135843A2 (fr) | Souche de lactobacillus fermentum pouvant empêcher la perte de cheveux, favoriser la pousse des cheveux, ou améliorer la fonction sexuelle, et composition comprenant cette souche | |
WO2018043864A1 (fr) | Souche de leuconostoc holzapfelii ayant pour effets de prévenir la perte des cheveux, de favoriser la pousse des cheveux ou d'améliorer la fonction sexuelle, et composition la comprenant | |
US7785581B2 (en) | Composition and method for reducing feces toxins and treating digestive disorders | |
WO2018043874A1 (fr) | Composition permettant de prévenir la chute des cheveux ou de favoriser la pousse des cheveux, comprenant des souches présentant un effet de lipolyse | |
WO2019199094A1 (fr) | Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l'obésité, et utilisation correspondante | |
WO2018030732A1 (fr) | Nanovésicules dérivées de bactéries du genre bacillus et leur utilisation | |
WO2022086041A1 (fr) | Nouvelle souche de lactobacillus sp. et son utilisation | |
WO2021194011A1 (fr) | Probiotiques pour prévenir ou traiter la maladie d'alzheimer, et composition alimentaire les comprenant pour prévenir ou traiter une maladie buccale | |
WO2023038418A1 (fr) | Souche de bifidobacterium bifidum eps da-laim pour le maintien de la santé intestinale, possédant l'effet de favoriser la croissance des lactobacilles, et polysaccharides qui en sont issus | |
WO2018135842A1 (fr) | Souche de brevibacillus reuszeri ayant la capacité de prévenir la chute des cheveux, de favoriser la croissance des cheveux ou d'améliorer la fonction sexuelle, et composition la comprenant | |
KR102004346B1 (ko) | 지방 분해능을 갖는 균주를 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
KR101790548B1 (ko) | 지방 분해능을 갖는 균주를 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
WO2019117654A1 (fr) | Probiotiques pour inhiber et prévenir l'évolution de maladies rénales et compositions pour inhiber et prévenir l'évolution de maladies rénales les comprenant | |
WO2013176327A1 (fr) | Composition pharmaceutique et aliment fonctionnel de santé pour la prévention ou le traitement de maladies osseuses, contenant un produit de fermentation de bactéries lactiques de soupe détox de coptis chinensis en tant que principe actif | |
WO2023177215A1 (fr) | Souche de weissella cibaria ayant une activité d'amélioration de la santé dentaire et son utilisation | |
WO2023177218A1 (fr) | Souche de lacticaseibacillus paracasei ayant une activité inhibitrice de pathogène parodontal, et son utilisation | |
WO2020045972A1 (fr) | Souche de lactobacillus fermentum mg4231 ou de lactobacillus fermentum mg4244 dérivé du corps humain, ayant une activité anti-obésité, et composition la comprenant | |
TWI810852B (zh) | 凝結芽孢桿菌bc198或其代謝產物用於預防或輔助治療化療導致腸道受損相關病變或菌叢失衡之用途 | |
KR101840376B1 (ko) | 탈모 예방, 발모 촉진 또는 성기능 개선능이 있는 락토바실러스 퍼멘텀 균주 및 이를 포함하는 조성물 | |
WO2024172497A1 (fr) | Souche de lacticaseibacillus rhamnosus et utilisations d'amélioration de l'immunité associées | |
KR101882303B1 (ko) | 지방 분해능을 갖는 균주를 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
KR20180085668A (ko) | 탈모 예방, 발모 촉진 또는 성기능 개선능이 있는 브레비바실러스 루제리 균주 및 이를 포함하는 조성물 | |
WO2022108392A1 (fr) | Composition théragnostique pour la sclérodermie, contenant bifidobacterium sp. comme ingrédient actif | |
WO2024117705A1 (fr) | Composition pharmaceutique pour soulager ou traiter le syndrome prémenstruel comprenant la souche d'enterococcus lactis lcm001 | |
WO2024029670A1 (fr) | Lactobacillus helveticus bcc-lh-04 présentant une activité de réduction de la graisse corporelle, et compositions le contenant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18741808 Country of ref document: EP Kind code of ref document: A2 |